Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3033% below fair value
$3.69−0.21 (-5.38%)
Close on Nov 18, 2026Market cap $104.15MP/E –Yield –
Journey Medical revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Journey Medical's revenue for the twelve months ending Jun 30, 2026 was $68.18M, up 20.9% year over year. For fiscal 2025 it was $61.86M, up 10.2% from the year before. The highest annual figure on record is $79.18M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.86M | +10.2% |
| FY2024 | Dec 31, 2024 | $56.13M | -29.1% |
| FY2023 | Dec 31, 2023 | $79.18M | +7.5% |
| FY2022 | Dec 31, 2022 | $73.67M | +16.7% |
| FY2021 | Dec 31, 2021 | $63.13M | +41.8% |
| FY2020 | Dec 31, 2020 | $44.53M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $18.51M | +23.3% |
| Q1 FY2026 | Mar 31, 2026 | $15.96M | +21.5% |
| Q4 FY2025 | Dec 31, 2025 | $16.08M | +18.1% |
| Q3 FY2025 | Sep 30, 2025 | $17.63M | +20.5% |
| Q2 FY2025 | Jun 30, 2025 | $15.01M | +1.0% |
| Q1 FY2025 | Mar 31, 2025 | $13.14M | +0.8% |
| Q4 FY2024 | Dec 31, 2024 | $13.62M | -10.7% |
| Q3 FY2024 | Sep 30, 2024 | $14.63M | -57.6% |
| Q2 FY2024 | Jun 30, 2024 | $14.86M | -7.0% |
| Q1 FY2024 | Mar 31, 2024 | $13.03M | -19.1% |
| Q4 FY2023 | Dec 31, 2023 | $15.26M | -16.6% |
| Q3 FY2023 | Sep 30, 2023 | $34.54M | +48.3% |
| Q4 FY2022 | Dec 31, 2022 | $15.97M | -8.9% |
| Q3 FY2022 | Sep 30, 2022 | $16.12M | -17.8% |
| Q2 FY2022 | Jun 30, 2022 | $18.29M | +19.6% |
| Q1 FY2022 | Mar 31, 2022 | $23.30M | +117.3% |
| Q4 FY2021 | Dec 31, 2021 | $17.52M | +27.6% |
| Q3 FY2021 | Sep 30, 2021 | $19.61M | +107.6% |
| Q2 FY2021 | Jun 30, 2021 | $15.29M | – |
| Q1 FY2021 | Mar 31, 2021 | $10.72M | – |
| Q4 FY2020 | Dec 31, 2020 | $13.72M | – |
| Q3 FY2020 | Sep 30, 2020 | $9.45M | – |
See a number that looks wrong?